Reply

Affiliations

¹ Ophthalmology Department, Campus Bio-Medico University, Rome, Italy.
² Sense Organs Department, Sapienza University, Rome, Italy. Electronic address: alessandro.lambiase@uniroma1.it.

Comment

Stefano Bonini et al. Ophthalmology. 2019 Feb.

. 2019 Feb;126(2):e15-e16.

doi: 10.1016/j.ophtha.2018.09.018.

¹ Ophthalmology Department, Campus Bio-Medico University, Rome, Italy.
² Sense Organs Department, Sapienza University, Rome, Italy. Electronic address: alessandro.lambiase@uniroma1.it.

No abstract available

Comment on

Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F; REPARO Study Group. Bonini S, et al. Ophthalmology. 2018 Sep;125(9):1332-1343. doi: 10.1016/j.ophtha.2018.02.022. Epub 2018 Apr 10. Ophthalmology. 2018. PMID: 29653858 Clinical Trial.
Re: Bonini et al.: Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis (Ophthalmology. 2018;125:1332-1343).
Ting DSJ. Ting DSJ. Ophthalmology. 2019 Feb;126(2):e14-e15. doi: 10.1016/j.ophtha.2018.09.017. Ophthalmology. 2019. PMID: 30683186 No abstract available.